A new first-in-human phase 1 trial, has been posted for JUR-003 in metastatic prostate cancer. The study plans to enrol up to 210 patients and includes dose-escalation and dose-expansion cohorts in mCRPC, metastatic hormone-sensitive prostate cancer (mHSPC) and oligometastatic disease. JUR-003 will be given intravenously, with the initial goals of defining safety, pharmacokinetics and a […]
A new 2026 review proposes an interesting idea: bipolar androgen therapy (BAT) may help make prostate cancer more sensitive to PARP inhibitors, even in some tumours that do not carry the classic BRCA1/2 mutations usually associated with strong PARP responses. BAT exposes prostate cancer cells to rapid swings between very high and very low testosterone […]
We already discussed ENV105 (carotuximab) in a previous ProstateWarriors article, when the safety lead-in of its phase 2 trial in metastatic castration-resistant prostate cancer was completed. Since then, the programme has produced its first meaningful efficacy signal, making it worth revisiting. ENV105 targets CD105, a protein that appears to become more active as prostate cancer […]
A new preclinical study published in Cancer Research has identified a possible way to attack prostate cancer that has become resistant to castration and enzalutamide. The work focuses on BUB1B, a protein involved in controlling cell division, and CENP-E, one of the proteins it helps regulate. When researchers lowered BUB1B levels, resistant prostate cancer cells […]
An inexpensive antifungal drug that has been used for decades is now being tested as a prostate cancer treatment. The phase 2 TerbinaPro trial is evaluating terbinafine in men whose prostate cancer has returned biochemically after previous treatment. Behind this unusual drug-repurposing trial lies an intriguing discovery about how prostate cancer produces cholesterol. The target […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Summer is over, research publishing has picked up again, and this week we have plenty of interesting information to read! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the […]
Prostate cancer that develops neuroendocrine features is commonly associated with loss of androgen-receptor dependence and reduced PSMA expression, potentially making PSMA-targeted treatments less useful. A new dual-tracer imaging study suggests that the reality may be considerably more complicated. Researchers retrospectively examined eight men with metastatic castration-resistant prostate cancer who were suspected of developing treatment-emergent neuroendocrine […]
A new retrospective study with a 10-year follow-up suggests that some men with prostate cancer recurring only in lymph nodes may achieve prolonged disease control using PET-directed radiotherapy combined with temporary androgen deprivation therapy (ADT). The retrospective study included 93 men with hormone-sensitive prostate cancer that had returned in pelvic and/or para-aortic lymph nodes after […]
A next-generation PARP inhibitor called SNV1521 is showing early signs of activity in advanced prostate cancer, while potentially causing less bone-marrow toxicity than existing PARP drugs. SNV1521 is an oral drug designed to selectively inhibit PARP1 while largely sparing PARP2. Current PARP inhibitors such as olaparib inhibit both proteins, and suppression of PARP2 is thought […]
A new analysis of the PRINCE clinical trial suggests that combining blood-based ctDNA testing with PSMA PET could help identify which men with metastatic castration-resistant prostate cancer (mCRPC) are most likely to respond to Lu-177 PSMA plus immunotherapy. PRINCE was a multicentre Phase 1/2 trial involving 37 men with mCRPC. Patients received up to six […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy